Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.
Identifieur interne : 002079 ( PubMed/Curation ); précédent : 002078; suivant : 002080Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.
Auteurs : T. Gauthier [France] ; A. Garuchet-Bigot ; B. Marin ; J. Mollard ; O. Loum ; V. Fermeaux ; I. Jammet ; D. Kanoun ; A. Maubon ; Y. AubardSource :
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [ 1532-2157 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Aisselle, Exsudats et transsudats (), Femelle, Gels, Humains, Invasion tumorale (anatomopathologie), Jeune adulte, Lymphadénectomie (), Lymphadénectomie (effets indésirables), Lymphe (), Lymphoedème (), Lymphoedème (étiologie), Mastectomie (), Méthode en double aveugle, Noeuds lymphatiques (), Noeuds lymphatiques (anatomopathologie), Peptides cycliques (usage thérapeutique), Résultat thérapeutique, Soins préopératoires (), Somatostatine (analogues et dérivés), Somatostatine (usage thérapeutique), Stade de la tumeur, Statistique non paramétrique, Sujet âgé, Sujet âgé de 80 ans ou plus, Sérome (), Tumeurs du sein (), Tumeurs du sein (anatomopathologie), Valeurs de référence, Études de suivi, Études prospectives, Évaluation des risques.
- MESH :
- analogues et dérivés : Somatostatine.
- anatomopathologie : Invasion tumorale, Noeuds lymphatiques, Tumeurs du sein.
- effets indésirables : Lymphadénectomie.
- usage thérapeutique : Peptides cycliques, Somatostatine.
- étiologie : Lymphoedème.
- Adulte, Adulte d'âge moyen, Aisselle, Exsudats et transsudats, Femelle, Gels, Humains, Jeune adulte, Lymphadénectomie, Lymphe, Lymphoedème, Mastectomie, Méthode en double aveugle, Noeuds lymphatiques, Résultat thérapeutique, Soins préopératoires, Stade de la tumeur, Statistique non paramétrique, Sujet âgé, Sujet âgé de 80 ans ou plus, Sérome, Tumeurs du sein, Valeurs de référence, Études de suivi, Études prospectives, Évaluation des risques.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Axilla, Breast Neoplasms (pathology), Breast Neoplasms (surgery), Double-Blind Method, Exudates and Transudates (drug effects), Female, Follow-Up Studies, Gels, Humans, Lymph (drug effects), Lymph Node Excision (adverse effects), Lymph Node Excision (methods), Lymph Nodes (pathology), Lymph Nodes (surgery), Lymphedema (etiology), Lymphedema (prevention & control), Mastectomy (methods), Middle Aged, Neoplasm Invasiveness (pathology), Neoplasm Staging, Peptides, Cyclic (therapeutic use), Preoperative Care (methods), Prospective Studies, Reference Values, Risk Assessment, Seroma (prevention & control), Somatostatin (analogs & derivatives), Somatostatin (therapeutic use), Statistics, Nonparametric, Treatment Outcome, Young Adult.
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , therapeutic use : Peptides, Cyclic, Somatostatin.
- chemical : Gels.
- adverse effects : Lymph Node Excision.
- drug effects : Exudates and Transudates, Lymph.
- etiology : Lymphedema.
- methods : Lymph Node Excision, Mastectomy, Preoperative Care.
- pathology : Breast Neoplasms, Lymph Nodes, Neoplasm Invasiveness.
- prevention & control : Lymphedema, Seroma.
- surgery : Breast Neoplasms, Lymph Nodes.
- Adult, Aged, Aged, 80 and over, Axilla, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Prospective Studies, Reference Values, Risk Assessment, Statistics, Nonparametric, Treatment Outcome, Young Adult.
Abstract
The aim of this study was to assess the efficacy of Lanreotide Autogel 90 mg PR to prevent lymphorrhea after axillary dissection in breast cancer.
DOI: 10.1016/j.ejso.2012.05.009
PubMed: 22703757
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002079
Links to Exploration step
pubmed:22703757Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.</title><author><name sortKey="Gauthier, T" sort="Gauthier, T" uniqKey="Gauthier T" first="T" last="Gauthier">T. Gauthier</name><affiliation wicri:level="1"><nlm:affiliation>CHU Limoges, Hopital Mère-Enfant, Institut du Sein, av Larrey, Limoges F-87000, France. gauthiertristan@yahoo.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU Limoges, Hopital Mère-Enfant, Institut du Sein, av Larrey, Limoges F-87000</wicri:regionArea></affiliation></author><author><name sortKey="Garuchet Bigot, A" sort="Garuchet Bigot, A" uniqKey="Garuchet Bigot A" first="A" last="Garuchet-Bigot">A. Garuchet-Bigot</name></author><author><name sortKey="Marin, B" sort="Marin, B" uniqKey="Marin B" first="B" last="Marin">B. Marin</name></author><author><name sortKey="Mollard, J" sort="Mollard, J" uniqKey="Mollard J" first="J" last="Mollard">J. Mollard</name></author><author><name sortKey="Loum, O" sort="Loum, O" uniqKey="Loum O" first="O" last="Loum">O. Loum</name></author><author><name sortKey="Fermeaux, V" sort="Fermeaux, V" uniqKey="Fermeaux V" first="V" last="Fermeaux">V. Fermeaux</name></author><author><name sortKey="Jammet, I" sort="Jammet, I" uniqKey="Jammet I" first="I" last="Jammet">I. Jammet</name></author><author><name sortKey="Kanoun, D" sort="Kanoun, D" uniqKey="Kanoun D" first="D" last="Kanoun">D. Kanoun</name></author><author><name sortKey="Maubon, A" sort="Maubon, A" uniqKey="Maubon A" first="A" last="Maubon">A. Maubon</name></author><author><name sortKey="Aubard, Y" sort="Aubard, Y" uniqKey="Aubard Y" first="Y" last="Aubard">Y. Aubard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22703757</idno><idno type="pmid">22703757</idno><idno type="doi">10.1016/j.ejso.2012.05.009</idno><idno type="wicri:Area/PubMed/Corpus">002079</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002079</idno><idno type="wicri:Area/PubMed/Curation">002079</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002079</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.</title><author><name sortKey="Gauthier, T" sort="Gauthier, T" uniqKey="Gauthier T" first="T" last="Gauthier">T. Gauthier</name><affiliation wicri:level="1"><nlm:affiliation>CHU Limoges, Hopital Mère-Enfant, Institut du Sein, av Larrey, Limoges F-87000, France. gauthiertristan@yahoo.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU Limoges, Hopital Mère-Enfant, Institut du Sein, av Larrey, Limoges F-87000</wicri:regionArea></affiliation></author><author><name sortKey="Garuchet Bigot, A" sort="Garuchet Bigot, A" uniqKey="Garuchet Bigot A" first="A" last="Garuchet-Bigot">A. Garuchet-Bigot</name></author><author><name sortKey="Marin, B" sort="Marin, B" uniqKey="Marin B" first="B" last="Marin">B. Marin</name></author><author><name sortKey="Mollard, J" sort="Mollard, J" uniqKey="Mollard J" first="J" last="Mollard">J. Mollard</name></author><author><name sortKey="Loum, O" sort="Loum, O" uniqKey="Loum O" first="O" last="Loum">O. Loum</name></author><author><name sortKey="Fermeaux, V" sort="Fermeaux, V" uniqKey="Fermeaux V" first="V" last="Fermeaux">V. Fermeaux</name></author><author><name sortKey="Jammet, I" sort="Jammet, I" uniqKey="Jammet I" first="I" last="Jammet">I. Jammet</name></author><author><name sortKey="Kanoun, D" sort="Kanoun, D" uniqKey="Kanoun D" first="D" last="Kanoun">D. Kanoun</name></author><author><name sortKey="Maubon, A" sort="Maubon, A" uniqKey="Maubon A" first="A" last="Maubon">A. Maubon</name></author><author><name sortKey="Aubard, Y" sort="Aubard, Y" uniqKey="Aubard Y" first="Y" last="Aubard">Y. Aubard</name></author></analytic><series><title level="j">European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</title><idno type="eISSN">1532-2157</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Axilla</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (surgery)</term><term>Double-Blind Method</term><term>Exudates and Transudates (drug effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Gels</term><term>Humans</term><term>Lymph (drug effects)</term><term>Lymph Node Excision (adverse effects)</term><term>Lymph Node Excision (methods)</term><term>Lymph Nodes (pathology)</term><term>Lymph Nodes (surgery)</term><term>Lymphedema (etiology)</term><term>Lymphedema (prevention & control)</term><term>Mastectomy (methods)</term><term>Middle Aged</term><term>Neoplasm Invasiveness (pathology)</term><term>Neoplasm Staging</term><term>Peptides, Cyclic (therapeutic use)</term><term>Preoperative Care (methods)</term><term>Prospective Studies</term><term>Reference Values</term><term>Risk Assessment</term><term>Seroma (prevention & control)</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (therapeutic use)</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Aisselle</term><term>Exsudats et transsudats ()</term><term>Femelle</term><term>Gels</term><term>Humains</term><term>Invasion tumorale (anatomopathologie)</term><term>Jeune adulte</term><term>Lymphadénectomie ()</term><term>Lymphadénectomie (effets indésirables)</term><term>Lymphe ()</term><term>Lymphoedème ()</term><term>Lymphoedème (étiologie)</term><term>Mastectomie ()</term><term>Méthode en double aveugle</term><term>Noeuds lymphatiques ()</term><term>Noeuds lymphatiques (anatomopathologie)</term><term>Peptides cycliques (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Soins préopératoires ()</term><term>Somatostatine (analogues et dérivés)</term><term>Somatostatine (usage thérapeutique)</term><term>Stade de la tumeur</term><term>Statistique non paramétrique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sérome ()</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Valeurs de référence</term><term>Études de suivi</term><term>Études prospectives</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Peptides, Cyclic</term><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Gels</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymph Node Excision</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Somatostatine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Invasion tumorale</term><term>Noeuds lymphatiques</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Exudates and Transudates</term><term>Lymph</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lymphadénectomie</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Lymph Node Excision</term><term>Mastectomy</term><term>Preoperative Care</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term><term>Lymph Nodes</term><term>Neoplasm Invasiveness</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Lymphedema</term><term>Seroma</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Peptides cycliques</term><term>Somatostatine</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Axilla</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prospective Studies</term><term>Reference Values</term><term>Risk Assessment</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Aisselle</term><term>Exsudats et transsudats</term><term>Femelle</term><term>Gels</term><term>Humains</term><term>Jeune adulte</term><term>Lymphadénectomie</term><term>Lymphe</term><term>Lymphoedème</term><term>Mastectomie</term><term>Méthode en double aveugle</term><term>Noeuds lymphatiques</term><term>Résultat thérapeutique</term><term>Soins préopératoires</term><term>Stade de la tumeur</term><term>Statistique non paramétrique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sérome</term><term>Tumeurs du sein</term><term>Valeurs de référence</term><term>Études de suivi</term><term>Études prospectives</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to assess the efficacy of Lanreotide Autogel 90 mg PR to prevent lymphorrhea after axillary dissection in breast cancer.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22703757</PMID><DateCreated><Year>2012</Year><Month>09</Month><Day>18</Day></DateCreated><DateCompleted><Year>2012</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2157</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</Title><ISOAbbreviation>Eur J Surg Oncol</ISOAbbreviation></Journal><ArticleTitle>Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>902-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejso.2012.05.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0748-7983(12)00329-0</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study was to assess the efficacy of Lanreotide Autogel 90 mg PR to prevent lymphorrhea after axillary dissection in breast cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A Phase III double-blind, randomized, placebo-controlled trial was performed between April 1st, 2008, and December 31st, 2010. The primary endpoint was the lymphorrhea volume (ml) in the axillary drain during the first four postoperative days. The secondary end points were the number of days until axillary drain removal, hospital stay duration (days), lymphorrhea volume (ml) up to days 15, 30 and 180, number of cases with seroma aspiration and number of seroma aspirations, evaluation of wound, arm pain and mobility on days 15, 30 and 180.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 148 patients were recruited for the study. Altogether 145 patients were randomized and analysed on an intention-to-treat basis. On the day before surgery 73 patients received the placebo and 72 patients received lanreotide. At four postoperative days, there was a tendency towards a reduction of the lymphorrhea volume in the lanreotide group (median 292 ml, range 1-965 ml) as compared to the placebo group (median 337 ml, range 0-1230 ml), although it was not statistically significant (p = 0.18). There was no significant difference for the secondary end points. In the group with axillary dissection performed alone (n = 24), the lymphorrhea volume was shown to be significantly reduced in the lanreotide group, (p = 0.035) as compared to the placebo group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study did not identify any overall significant reduction of lymphorrhea on lanreotide.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CHU Limoges, Hopital Mère-Enfant, Institut du Sein, av Larrey, Limoges F-87000, France. gauthiertristan@yahoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garuchet-Bigot</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mollard</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Loum</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Fermeaux</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Jammet</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Kanoun</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Maubon</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Aubard</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Surg Oncol</MedlineTA><NlmUniqueID>8504356</NlmUniqueID><ISSNLinking>0748-7983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005782">Gels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0G3DE8943Y</RegistryNumber><NameOfSubstance UI="C060347">lanreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance UI="D013004">Somatostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005122" MajorTopicYN="N">Exudates and Transudates</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008196" MajorTopicYN="N">Lymph</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010456" MajorTopicYN="N">Peptides, Cyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049291" MajorTopicYN="N">Seroma</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013004" MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>01</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>05</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22703757</ArticleId><ArticleId IdType="pii">S0748-7983(12)00329-0</ArticleId><ArticleId IdType="doi">10.1016/j.ejso.2012.05.009</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002079 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002079 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22703757
|texte= Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22703757" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |